Milestone payment
MorphoSys AG said its partner, Centocor Inc, enrolled the first patient in a Phase II clinical trial of a fully human antibody based on Morphosys’ HUCAL technology. The move triggers a milestone payment to the Martinsreid, Germany–based company.
A Phase I clinical trial using the same antibody in oncology patients started in 2007 and is ongoing. The new trial is in an immunology indication.
“[This] marks further significant progress within our partnered therapeutic antibody business and underpins the variety of commercial opportunities inherent in our pipeline,” said Simon Moroney, Chief Executive Officer of MorphoSys.
“Broadening [their use] is at the heart of the commercial success of several antibody therapies currently on the market. For MorphoSys, additional indications represent further value for our partnered drug pipeline, as [they] lead to higher clinical milestones and royalty-based income.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
